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Progress in the understanding of the pathophysiology of irritable bowel syndrome (IBS), once thought to be a purely
psychosomatic disease, has advanced considerably and low-grade inﬂammation and changes in the gut microbiota now feature as
potentially important. The human gut harbours a huge microbial ecosystem, which is equipped to perform a variety of functions
such as digestion of food, metabolism of drugs, detoxiﬁcation of toxic compounds, production of essential vitamins, prevention of
attachmentofpathogenicbacteriatothegutwall,andmaintenanceofhomeostasisinthegastrointestinaltract.Asubsetofpatients
withIBSmayhaveaquantitativeincreaseinbacteriainthesmallbowel(smallintestinalbacterialovergrowth).Qualitativechanges
in gut microbiota have also been associated with IBS. Targeting the gut microbiota using probiotics and antibiotics has emerged
as a potentially eﬀective approach to the treatment of this, hitherto enigmatic, functional bowel disorder. The gut microbiota in
health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with
IBS are reviewed in this paper.
1.Introduction
Functional bowel disorders, including irritable bowel syn-
drome (IBS), are common gastrointestinal disorders all over
theworld.Previously,IBSwasthoughttobeapsychosomatic
disorder. However, in the last few decades, advances in our
understanding of the pathophysiology of IBS have revealed
several factors, including alterations in the microbiota, as
potentially relevant to the cause of this syndrome and the
precipitation of its symptoms. Indeed, alterations in the
gut microbiota are being increasingly implicated in the
pathogenesisofseveralgastrointestinalandsystemicdiseases.
We wish, therefore, to review the gut microbiota and its
alterations in, and relationships to, IBS.
2.GutMicrobiotainHealth
The human gut harbours a huge microbial ecosystem, which
is equipped to perform a variety of functions such as the
digestion of food, metabolism of the drugs, detoxiﬁcation
of toxic compounds, production of essential vitamins,
prevention of attachment of pathogenic bacteria to the gut
wall and maintenance of homeostasis in the gastrointestinal
tract (GIT) [1–3]. The human gut is ﬁrst colonized at birth;
this microbiota gradually increases in size and diversity up
to the end of the ﬁrst year of life; by that time, the gut
microbiota has come to resemble that of the adult and
remains relatively stable thereafter [4]. The composition
of the gut microbiota varies according to age, sex, diet,
geographical origin of the individual and is also inﬂuenced2 International Journal of Inﬂammation
by certain environmental factors, such as administration
of antibiotics [1]. The composition and activity of the
human gut microbiota aﬀect gastrointestinal and systemic
homeostasis. There are 10times more microbial cells (1014)
in the gut than cells in the entire body (1013)[ 3]. A recent
study has suggested that the human gut microbiota consists
of more than 35,000 bacterial species and that 70% of all of
microbes in the human body reside in the colon [4]. The
small intestine consists of mainly Gram-positive and aerobic
bacteria, whereas the large intestine consists largely of Gram-
negative and strictly anaerobic bacteria [5, 6].
3. Alteration of Gut Microbiota
Alterationsinthenormalgutmicrobiotahavebeensuggested
as etiologic factors in the development of functional gas-
trointestinal disorders such as IBS and functional dyspepsia,
common GI disorders of unknown etiology [7–9]. Quantita-
tive alterations in the gut microbiota in the small bowel may
result in the clinical syndrome recognized as small intestinal
bacterial overgrowth (SIBO) [10]. In SIBO, such is the
change in the number and type of bacteria in the upper small
intestine that diarrhea, abdominal bloating, malabsorption,
abdominal pain, and excessive gas production result; severe
motor dysfunction may be an underlying cause [11–13].
Quantitative changes in the colonic microbiota may lead
to the proliferation and development of speciﬁc species that
produce more short-chain fatty acids (SCFAs) and gases,
such as methane, hydrogen, and carbon dioxide, potentially
resulting in abdominal bloating and distension. An increase
in the concentration of SCFAs (acetate, butyrate, and propi-
onate) leads to acidiﬁcation of the colon and deconjugation
of bile acid. This in turn may cause signiﬁcant changes in
water and electrolyte transport in the colon which result
in diarrhea [8, 14, 15]. Malabsorption of carbohydrates
may cause increased production of hydrogen gas, which is
associated mainly with diarrhea-predominant IBS (IBS-D)
[16] whilst excess methane gas production is associated with
constipation-predominant IBS (IBS-C) [14].
4.IrritableBowel Syndrome
IBS is a functional gastrointestinal disorder associated with
abdominal discomfort or pain, distension and bloating,
diarrhea, constipation, or mixed bowel habits (i.e., both
constipation and diarrhea; IBS-M). IBS subjects may also
experience greater levels of stress, anxiety, and depression
compared to healthy subjects [16, 17]. All of these co-mor-
bidities are associated with impaired quality of life in IBS
patients [18–20]. Several diagnostic criteria (Kruis, Man-
ning, Rome) have been used to distinguish IBS patients from
those with organic bowel disease in daily clinical practice
[11, 21].
The prevalence of IBS varies from 9% to 22% in the
United States and Europe [22, 23]. In Asian countries, IBS
aﬀects 4% to 20% of populations. In Asia, the lowest preva-
lence has been reported from India, at 4.2%, and the highest
from Japan and Singapore [23–25].
The exact etiology and pathophysiology of IBS remain
unclear. Several hypotheses have been proposed which
include alteration in the gut microbiota, dysregulation of the
brain-gut axis and autonomic nervous system, visceral hy-
persensitivity,andalteredlevelsofgastrointestinalneuropep-
tides and hormones [11, 22, 26]. Furthermore, abnormal
gastrointestinal motility, as well as genetic, environmental,
and psychological factors, may also play important roles in
the development of IBS. Recent studies have also shown
that IBS is associated with low-grade intestinal inﬂammation
resulting from an activated immune system, in response to a
normal or abnormal gut microbiota [1, 27, 28].
5.Pathophysiology
5.1. Altered Gut Microbiota or Dysbiosis. There is a growing
interest in investigating the role of an altered gut microbiota
in the pathogenesis of IBS [14, 29]. Normal gut microbiota
have either direct bactericidal eﬀects or can prevent the
adherence of pathogenic bacteria to the wall of the gastroin-
testinal tract [7, 30, 31]. Dysbiosis in the gut may facilitate
the adhesion of enteric pathogens in the human gut which
can be associated with IBS symptoms [30, 32]. Alteration
in the composition of the normal microbiota and disturbed
colonic fermentation in IBS patients may play an important
role in development of IBS symptoms [33]. Firmicutes and
Bacteroidetes are the major beneﬁcial gut microbiota in the
normal human and changes in their relative numbers have
been reported in IBS patients [1]. Signiﬁcantly, a two-fold
increase in the ratio of Firmicutes to Bacteroidetes has been
reported in IBS patients. This results from an increase in the
quantity of Ruminococcus, Clostridium, Dorea species and a
decrease in the quantity of Biﬁdobacterium and Faecalibac-
teriumspecies[34].Signiﬁcantlygreaterabundanceofclasses
of Gammaproteobacteria and Enterobacteriaceae in healthy
controls were positively correlated with the inﬂammatory
markers IL-6 and IL-8. Higher levels of these cytokines have
been reported in IBS patients [34, 35]. Due to a diﬀerent
microenvironment in the intestinal epithelium and lumen,
the composition of microbiota is not the same at the level of
the gut epithelium and lumen [33]. Culture-based analysis
had shown that there were signiﬁcant diﬀerences between
the mucosa-associated microbiota and fecal samples in both
healthy control and IBS patients. For example, a signiﬁcantly
increased quantity of aerobic bacteria and Lactobacillus was
noted in IBS-D in feces but not in mucosal samples [19].
Several studies using diﬀerent methodologies to deﬁne
changes in the microbiota have been published, includ-
ing classic culture-based techniques, PCR-based molecular
technologies such as real-time PCR (q PCR), microarray,
DGGE (denaturation gradient gel electrophoresis), GC pro-
ﬁling, and high-throughput sequencing based on 16s rRNA
[33, 36] (see Table 1).
Bacterial fermentation of undigested, unabsorbed food
causes production of SCFAs, which are bacteriostatic for a
group of species, either directly or by reducing pH [2, 7, 30,
31, 37]. SIBO causes unusual fermentation with increases
in gas production and abnormal gastrointestinal motility. AInternational Journal of Inﬂammation 3
Table 1: Summary of the studies on the alteration in gut microbiota in IBS subjects.
S. No. IBS (n) Healthy
(n)
Diagnostic
criteria Method Outcome Reference
1 11 8 Rome II PCR and DGGE
Diversity of total bacteria
along with Lacto bacillus was
higher in IBS patients than
healthy control
Ponnusamy et al. [1]
22 4 2 3 R o m e I I
Nucleic acid
fractionation according
to GC content, cloning
followed by sequencing
and qPCR
Collinsella aerofaciens,
Clostridium cocleatum, and
Coprococcus eutactus
conﬁrmed signiﬁcant
diﬀerence from that of healthy
subjects
Kassinen et al. [18]
3 10 10 Rome III Culture and q PCR
Signiﬁcantly decreased
quantity of aerobic bacteria in
IBS than healthy control and
increased concentration of
Lactobacillus species in D-IBS
patients than healthy control
Carroll et al. [19]
4 37 20 Rome II DGGE and q PCR
Signiﬁcant increase in the
amount of Pseudomonas
aeruginosa in IBS patients
Kerckhoﬀse ta l .[ 33]
51 6 1 6 R o m e I I
RT-PCR-DGGE,
Transcript analysis with
the aid of aﬃnity
capture (TRAC)
Signiﬁcantly decreased
amount Clostridium
coccoides-E. rectale in IBS-C
Maukonen et al. [106]
6 41 26 Rome II FISH Analysis
Signiﬁcantly decreased
quantity of Biﬁdobacterium
catenulatum in faecal and
duodenal samples of IBS
patients than healthy control
Kerckhoﬀse ta l .[ 107]
74 4 3 4 R o m e I I C u l t u r e a n d P C R
Signiﬁcantly increased
quantity of Enteraggroegative
Escherichia coli in IBS-D
Sobieszcza´ nska et al.
[108]
82 0 1 5 R o m e I I q P C R
Decreased quantity of
Clostridium thermosuccinogens
in IBS-D patients and
increased quantity of
Ruminococcus torque in IBS-D
patients than healthy control.
Ruminococcus bromii was
more abundant in IBS-C than
healthy control
Lyra et al. [109]
91 2 2 2 R o m e I I
%G+C proﬁling and
fractioned DNA
sequencing followed by
qP C R
Signiﬁcantly increased
quantity of Proteobacteria and
Firmicutes and reduced
quantity of Actinobacteria and
Bacteroidetes in IBS-D patients
than healthy control
Krogius-Kurikka et al.
[110]
10 25 25 Rome II Culture
Signiﬁcantly reduced number
of Biﬁdobacterium and
increased number of
Enterobacteriaceae in IBS
patients than healthy control
Si et al. [111]4 International Journal of Inﬂammation
Table 1: Continued.
S. No. IBS (n) Healthy
(n)
Diagnostic
criteria Method Outcome Reference
11 47 33 Rome II DGGE of 16S rRNA
Signiﬁcant diﬀerence in gut
microbiota in IBS patients and
healthy control along with
more variation in the gut
microbiota in control than
IBS subjects
Codling et al. [112]
12 26 26 Rome II Culture and q PCR
Signiﬁcantly increased
quantity of Lactobacillus and
Veillonella in IBS patients than
control
Tana et al. [113]
13 10 10 Rome III PCR and
Pyrosequencing
Signiﬁcantly increased
number of Bacteroidetes and
Synergistetes and reduced
number of Actinobacteria,
Bacilli, Flavobacteria, and
Epsilonproteobacteria in IBS
than control
Ng et al. [114]
14 22 22 Rome III
Metagenomics of 16S
rRNA gene followed by
PhyloChip hybridization
and Pyrosequencing
Signiﬁcantly greater
abundance of class
γ-Proteobacteria in IBS
children than healthy control
and Haemophilus
parainﬂuenzae was prominent
Saulnier et al. [35]
15 62 46 Rome II q PCR and microarray
Signiﬁcantly 2-fold increased
ratio of Firmicutes to
Bacteroidetes in IBS patients
comparison with the healthy
control
Rajili´ c–Stojanovi´ ce t
al. [34]
IBS: irritable bowel syndrome; IBS-D: diarrhea predominant IBS; IBS-C: constipation predominant IBS; PCR: polymerase chain reaction; DGGE:
denaturation gradient gel electrophoresis; q PCR: real time PCR; FISH: ﬂuorescent in situ hybridization; TRAC: transcript analysis with the aid of aﬃnity
capture.
previous study reported that the prevalence of SIBO in IBS
subjects detected by lactulose hydrogen breath test was about
78% [14]. However, this study used the lactulose hydrogen
breath test which has now been shown to be prone to a
high rate of false positive result [38]a n dm a yh a v el e dt oa n
overestimation of its frequency.
5.2. Postinfectious IBS (PI-IBS). IBS develops in a subgroup
of individuals following an episode of acute gastrointestinal
infection, known as PI-IBS. Acute enteric infections are
characterized by abdominal discomfort, fever, vomiting,
bloating, and diarrhea, [14, 39, 40]. Fever and vomiting gen-
erally improve after a few days while abdominal discomfort,
diarrhea and bloating “persist” in those who develop PI-
IBS [39]. Risk factors for the development of PI-IBS include
younger age, female gender, prolonged duration of diarrhea,
the presence of bacterial pathogens, and psychological
morbidities including anxiety, frustration, and depression
[41–43].
The risk of IBS increased sixfold after an acute gastroin-
testinal infection and persists for up to 3 years [44, 45].
Recent studies have shown that PI-IBS develops in 3–30%
of individuals with bacterial gastroenteritis caused by a
number of enteric pathogens such as Campylobacter species,
Clostridium perfringens, Staphylococcus aureus, Bacillus ce-
reus, Shigella and viruses [7, 30, 32, 39].
The prevalence of PI-IBS in subjects who had suﬀered
from diarrhea whilst travelling in developing countries has
been estimated to be 7–14% [46]. The diagnosis of PI-
IBS was made according to Rome criteria for IBS among
individuals who did not have IBS previously but developed
it after the episode of acute gastroenteritis [14, 39]. Recent
studieshavesuggestedthatPI-IBSisassociatedwithdysbiosis
in the gut (induced either by enteric infection or by the use
of antibiotics), psychological factors (such as stress, anxiety,
and depression), genetic susceptibility of the host, persistent
activation of the host immune system, increased intestinal
permeability, and an increased number of enterochromaﬃn
cells in the gut [22, 39, 47].
Potentially harmful microorganisms and their metabo-
litescausethedisruptionoftightjunctionsbetweenepithelial
cells leading to increased mucosal permeability during
the acute phase of infection [48, 49]. The permeability
of the proximal small intestine in PI-IBS was shown toInternational Journal of Inﬂammation 5
besigniﬁcantly increased compared to controls [50]. Zona
occludens (ZO-1) are tight junction protein that link the
transmembrane domain. A lesser expression of ZO-1 has
been observed in biopsy samples of IBS subjects [51].
As a result of increased permeability of intestinal epithe-
lial cells, an inﬂux of immune cells including mast cells,
T lymphocytes, macrophages, and inﬂammatory mediators
such as IL-2, IL-1β, IL-6, IL10, TGF-β occurs after an
acute enteric infection [48, 49, 52, 53]. A growing body
of evidence indicates that mast cells and lymphocytes are
increased in the mucosa of both PI-IBS and IBS patients
[54]. T lymphocytes are signiﬁcantly increased in PI-IBS
compared with control subjects [52]. IL-1β is signiﬁcantly
increased in PI-IBS patients during and after the infection
compared with those subjects who do not develop PI-IBS
[53]. Certain cytokines such as IL-6 may also further change
gut permeability. Increased levels of IL-6 have been reported
in IBS subjects compared with healthy controls [49]. These
inﬂammatory mediators (IL-1α,I L - 1 β,I L - 6 ,I F N - γ) damage
the intestinal epithelial barrier and cause inﬂammation
[48]. Furthermore, the administration of antibiotics altered
the composition of the gut microbiota and inhibited the
expression of antimicrobial peptide Reg III γ produced by
commensal bacteria. Reg III γ strengthens the intestinal
epithelial barrier by inhibiting Gram-negative pathogens but
hasnoeﬀectonGram-positivebacteria;itsinhibitionresults,
therefore, in a favourable environment for enteric pathogens
to proliferate [4, 7, 55].
5.3. Small Intestinal Bacterial Overgrowth (SIBO). Normally,
the density of bacteria is much lower in the small intestine
than in the large intestine. There are 1010–12 colony-
forming units (cfu) per mL, 105–8 cfu/mL, 100–5 cfu/mL and
100–4 cfu/mLbacteriainthececum,terminalileum,proximal
ileum, and jejunum/duodenum, respectively [54, 56]. The
major families of bacteria in the small intestine include
Bacilli, Streptococcaceae, Actinobacteria, Actinomycinaea,
and Corynebacteriaceae [4]. Qualitative or quantitative
changes in the microbiota of small intestine may lead to
the clinical features of SIBO [56, 57]. In healthy individuals,
the normal bacterial count in the proximal small intestine
is ≤104 cfu/mL; SIBO is traditionally deﬁned by a bacterial
count of ≥105 cfu per mL in jejunal aspirate [2, 56].
Several techniques have been used for the diagnosis of SIBO,
which include the lactulose hydrogen (LHBT), 14Cx y l o s e
and glucose hydrogen (GHBT) breath tests and culture of
jejunal aspirate [13, 56, 58]. Hydrogen and methane are
normally produced in the large intestine but in case of
SIBO these gases are produced in the small bowel also
[13]. Methanobrevibacter smithii, Methanobrevibacter stadt-
manae, and, possibly, Coliform bacteria produce methane gas
[13, 14].
The jejunal aspirate culture has, traditionally, been used
asthegoldstandardtodiagnoseSIBO.Thelimitationsofthis
test however include invasiveness and the challenges posed
by attempting to culture all strains and species [54, 57];
therefore, hydrogen breath tests (GHBT or LHBT) are most
commonly used [59]. In a study where endoscopic jejunal
biopsy culture was used to diagnose SIBO, its sensitivity
and speciﬁcity were 83.5% and 97.2%, respectively [60]. The
prevalence of SIBO in IBS patients was 4% (based on the
deﬁnition of ≥105cfu/mL of bacteria in jejunal aspirate) and
no diﬀerent from that seen in healthy individuals [56]. In
contrast,in a study of 111 IBS subjects using LHBT, Pimentel
et al. reported a prevalence of SIBO of 84% in IBS (in
comparison to 20% in healthy individuals). Furthermore,
the administration of neomycin signiﬁcantly alleviated IBS
symptoms [61]. Recent published data have shown that,
using jejunal aspirate as the gold standard, double-peak
in LHBT only diagnoses one-third of SIBO patients; the
sensitivity and speciﬁcity of LHBT were 31% and 86% and
those of GHBT were 44% and 80%, respectively [62]. In
a separate study by Berthold, the sensitivity and speciﬁcity
of lactose-(13C) ureide breath test (LUBT) were 66.7% and
100% and those of GHBT 41.7% and 44.4%, respectively
[63]. The sensitivity and speciﬁcity after glucose were 62.5%
and 82% and after lactulose were 52% and 86%, respectively
[13]. The variation in LHBT and GHBT may be due to
diﬀerences in the diagnostic criteria used for selection of IBS
patients, ecological origin, nature of the substrate used, and
diagnostic methods [59].
The administration of antibiotics and probiotics reduced
not only gas-related problems but also IBS-like symptoms
[54, 56, 61, 64]. SIBO may arise due to hypochlorhydria,
altered intestinal motility [2, 56], altered bacteriostatic
properties of pancreatic and biliary secretion [65], and a
dysregulated immune response [2]. Proton pump inhibitors
(PPIs) may predispose to SIBO by decreasing acid secretion
in the stomach [66]. Theisen reported that the inhibition of
acid secretion related to the administration of omeprazole
led to an increased concentration of unconjugated bile acids.
Deconjugation of bile acids inhibits the absorption of fat
and lipid soluble vitamins [67]. Thus, the potential side
eﬀects of PPI include constipation, diarrhea, bloating, and
abdominal pain, symptoms whichresemblethose ofIBS [68]
(see Table 2).
5.4. Intestinal Barrier Dysfunction and Altered Immune
Response. Commensal bacteria provide a favourable envi-
ronment, prevent the adherence of pathogenic bacteria, and
modulate innate and adaptive immune responses [55, 69].
They also protect the intestinal epithelial cell (IEC) from an
inﬂammatory response. The intestinal epithelium contains
a large number of lymphocytes that can remove infected
epithelial cells [70].
Paneth cells found at the base of the intestinal gland
(crypt of Lieberkuhn) throughout the small intestine can
prevent the penetration of intestinal epithelium by com-
mensal and pathogenic bacteria [71]. IECs are protected
by a glycocalyx layer of mucus, the epithelial junction
adhesion complex, secretory IgA, chloride secretion, and
otherglycoproteins[30,55].Theintestinalbarrierconsistsof
the tight junction complex, adherin junctions, gap junctions,
anddesmosomes.Therearemorethan40typesofproteinsin
the tight junction complex, which play crucial role in main-
taining the permeability of the intestinal epithelium [72].
A leaky intestinal epithelium has been reported in subjects6 International Journal of Inﬂammation
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Figure 1: (1) Commensal bacteria (2) Pathogenic bacteria (3) Mucus layer (4) Intestinal epithelium (5) Peyer’s patch (6) Tight junction
protein (7) Paneth cell (8) Toll-like receptors (9) Dendritic cell (10) T cell (11) Degranulation of mast cells (12) Small intestinal bacterial
overgrowth. The intestinal microbes may form a natural barrier to pathogenic bacteria. Therefore, any qualitative or quantitative change in
the gut microbiota leads to the instability of the gut microbial ecosystem. It facilitates the entry of pathogenic bacteria and allows them to
adhere to the wall of the intestinal epithelial cell. Degranulation of mast cells releases substances that increase the permeability of mucosa
resultinginareductionintheintegrityofthetightjunctionalproteincomplex.Luminalbacteriaorbacterialproductssuchaspeptidoglycans
and lipopolysaccharides interact with Toll-like receptors on dendritic cells and macrophages. After processing, these cells present the antigen
to T cells leading to the production of cytokines, chemokines which cause inﬂammation in the gastrointestinal tract. Paneth cells are found
throughout the small intestine and secrete alpha defensins and lysozyme which, not only eliminate pathogenic bacteria, but also maintain
the integrity of the intestinal membrane. Lymphocytes are found in a more organized structure called lymphoid follicles. M cells play an
important role in transporting bacteria and microbial particles from the lumen to the lymphoid follicles. The areas around M cells, called
Peyer’s patches, facilitate the mucosal immune response.
with IBS, ulcerative colitis, Crohn’s disease, celiac disease,
and food-borne infections [72–75]. A recent study has
shown that MicroRNA-29a regulates the permeability of the
intestine through the generation of glutamine synthetase
in patients with IBS. Glutamine synthetase controls the
concentration of glutamine. Decreased concentration of glu-
tamine leads to an increase in the permeability of intestinal
epithelial cells (IEC), whilst the permeability of IECs can be
recovered by the supplementation of glutamine in patients
with IBS [75]. The administration of probiotics, fermented
milk (Streptococcus thermophilus, Lactobacillus bulagaris Lac-
tobacillus acidophilus, and Biﬁdobacterium longum)a n dL.
plantarum has been shown to strengthen the intestinal bar-
rier [72–74]. Paneth cells and enterocytes in the gut secrete
antimicrobial molecules such as angiogenin 4, defensins,
IgA antibodies, and RegIII γ. These antimicrobial peptides
destroypathogenicbacteriabyformingaporeinthebacterial
cell wall [7, 55, 76]. These data suggest that a symbiotic
relationship is present between commensal bacteria and the
host.
The composition of the gut microbiota inﬂuences the
development of the immune system. Any alterations in the
gut microbiota due to enteric infections, antibiotic therapy
or acid suppressive treatment lead to activation of both
the innate and adaptive immune responses [69]. Certain
commensal bacteria induce intestinal inﬂammation while
others regulate the immune response. Commensal bacteria
from the phylum of Bacteroidetes and Firmicutes have
been shown to induce T regulatory cells and inhibit Th17-
mediated inﬂammation. In contrast, the administration
of Biﬁdobacterium animalis subspecies inhibited intestinal
inﬂammation via a reduction of the commensal bacteria
Enterobacteriace [55, 77, 78].
Thus, the gut microbiota plays an important role in the
maintenance of homeostasis of various subpopulations of
T cells: regulatory T cells (Tregs), T helper 1 (Th1), and
T 17 (Th17) cells in the gut [79]. Low-grade inﬂammation in
the intestine in IBS patients is associated with the activation
of T lymphocytes and mast cells, increased expression of
proinﬂammatory cytokines such as IL-6 and IL-8, and
elevated levels of IL-1β,T N F - α, and IL-8 in peripheral blood
mononuclear cells [80, 81]. Signiﬁcantly increased levels of
TNF-α,I L - 1 β, and IL-6, stimulated by lipopolysaccharide
(LPS), have been reported in an IBS-D subgroup while
increased levels of LPS-stimulated IL-1β were described in
an IBS-C subgroup (Figure 1).
In PI-IBS, LPS-induced cytokines (TNF-α,I L - 1 β,a n d
IL-6) are signiﬁcantly increased when compared with
controls. IL-1β causes alteration in secretomotor function
duringinﬂammation[80].IncreasedconcentrationsofIL-1β
are associated with the development of IBS symptoms such
as alteration in bowel habits [81]. Elevated levels of IL-6 areInternational Journal of Inﬂammation 7
Table 2: Summary of prevalence of SIBO in IBS patients by diﬀerent diagnostic methods.
Diagnostic method N. of IBS
patients
N. of
controls
Percentage of
SIBO in IBS
subjects
Percentage of
SIBO in
controls
Reference
LHBT 76 40 44.7% 40.0% Park et al. [115]
LHBT 43 56 65% 7% Scarpellini et al. [116]
LHBT 127 — 43% — Carrara et al. [5]
LHBT 258 — 34.5% —
Mann and
Limoges-Gonzales
[117]
LHBT 98 — 65% — Nucera et al.
Lombardolll [118]
GHBT 59 37 23.7% 2.7% Sachdeva et al. [119]
GHBT 98 — 36% — Reddymasu et al.
[120]
GHBT 200 50 24.5% 6% Lombardo et al.
GHBT 1921 — 31% — Ford et al. [121]
GHBT 130 70 16.1% 4.2% Parodi et al. [122]
GHBT 225 100 11.1% 1% Rana et al. [123]
GHBT 204 — 46% — Majewski et al. [124]
GHBT 96 — 45.8% — Cuoco and
Salvangnini [125]
GHBT 65 102 31% 4% Lupascu et al. [126]
GHBT 129 51 8.5% 2% Ghoshal et al. [58]
Hydrogen 158 34 32.9% 17.9% Grover et al. [127]
Breath test and culture
of small bowel aspirate 162 26 4% 4% Posserud et al. [56]
Abbreviationsused:SIBO:smallintestinalbacterialovergrowth;IBS:irritablebowelsyndrome;LHBT:lactulosehydrogenbreathtest;GHBT:glucosehydrogen
breath test.
produced during stress,inﬂammation, and infectiousdisease
[82]. Thymus-derived T regulatory cells (Treg) are involved
in the suppression of inﬂammation in IBS, ulcerative colitis,
and Crohn’s disease through the inhibition of T eﬀectorcells.
It has been shown that T cells express high levels of CD25
Tregs in the colon in IBS patients. Therefore, any alteration
in the frequency of Tregs may lead to recruitment of immune
eﬀectors which, consequently, results in inﬂammation [83,
84].
Intestinal epithelial cells recognize pathogens by way of
pattern recognition receptors including Toll-like receptors
(TLRs)andnucleotide-oligomerization-domain-(NOD)like
receptors. They induce innate immune responses by the
transcription and translation of antimicrobial proteins and
theinductionofproinﬂammatorycytokinesandchemokines
through the NF-κBp a t h w a y[ 30, 70]. Ten TLRs have been
reported in man so far, which recognized various microbial
pathogens, including viruses, bacteria, fungi, and protozoa.
A recent study has reported upregulation of TLR 4 and TLR
5 and down-regulation of TLR 7 and TLR 8 in IBS patients
[28]. Increased levels of TLR 4 and TLR 5 indicate that their
cognate ligands, LPS and ﬂagellin, are also increased in IBS
patients. Since the ligand for TLR 7 and TLR 8 is single-
strandedRNA,decreasedlevelofTLR7/8suggestedthatviral
infectionmayalsoplayanimportantroleinthedevelopment
of IBS-like symptoms. Such infections have been reported in
relation to the development of PI-IBS. These data further
support that increased permeability is present in at least a
subgroup of IBS patients [28, 85].
β-defensin 2 is an antimicrobial protein secreted by
intestinal epithelial cells and induced by TLR 4. Increased
levels of β-defensin 2 have been reported in the intestine
of patients with either IBS or ulcerative colitis [84, 85].
Several studies have shown that commensal bacteria may
reduce inﬂammation, in part, by directly acting on dendritic
cells to stimulate the induction of IL-10 and regulatory T
cells (Treg). With an increase in the number of commensal
bacteria, dendritic cells provide signals to lymph nodes to
stimulate adaptive immune responses leading to induction
of IgA antibodies that wrap the luminal antigens and, thus,
prevent them from breaching the intestinal barrier and the
inhibition of the systemic immune response. Dendritic cells
can directly sample luminal pathogens without disruption
of tight junctions [30, 55, 86]. Degranulation of mast
cells releases histamine and other potent mediators that
can inﬂuence the function of the enteric nervous system
and smooth muscles, causing IBS-like symptoms [30]. In
addition, a study has shown that mast cells are signiﬁcantly
increased in the caecum in patients with IBS [87]. Tryptase,
a protease released by mast cells, has been reported to be8 International Journal of Inﬂammation
signiﬁcantly increased in the colonic mucosa of patients with
IBS. Increased concentrations of serine protease have been
reported in the stool of IBS subjects [30, 84].
5.5. Targeting the Microbiota
5.5.1. Probiotics. The observation of dysbiosis in the gut
microbiota, altered mucosal barrier function, activated im-
mune responses, and SIBO support a role for bacteria in the
pathogenesis of IBS [88]. Probiotics are live or attenuated
microorganisms which, when administered in suﬃcient
quantities, have been shown to improve gut epithelial in-
tegrity, as well as alleviate the symptoms of IBS [30, 88–
90]. Previous studies have shown that the administration
of adequate amounts of probiotics (live microorganisms)
may alleviate the symptoms of IBS, suppress proinﬂamma-
tory cytokines, and promote the integrity of the intestinal
barrier [3, 31]. One study showed that the consumption of
Biﬁdobacterium infantis 35624 was associated with prolifer-
ation of T regulatory cells, reduction of proinﬂammatory
cytokines, down regulation of T cells, reduced expression of
co-stimulatory molecules, and attenuation of NF-κB[ 86]. In
vitro, increased levels of proinﬂammatory cytokines (IL-12)
and decreased concentrations of the anti-inﬂammatory
cytokine (IL-10) by PBMCs have been reported in IBS
patients. The ratio of IL-10/IL-12 was altered in IBS patients
compared to healthy volunteers and the administration of
Biﬁdobacterium infantis normalised this ratio [90]. Probi-
otics also inhibit adhesion of enteric pathogens to the wall
of the gastrointestinal tract [30].
Probiotics should have the following characteristics: (1)
they must survive in the gastrointestinal tract following
passage and eventually reside in the colon, (2) they must
not have a major adverse eﬀect on other beneﬁcial bacteria
in the gut, (3) they should be hostile to mutagenic or path-
ogenic organisms in the gut, and (4) they must be sta-
ble genetically [91]. In clinical studies, probiotics have
been shown to improve infectious or secretory diarrhea,
traveller’s diarrhea, and antibiotic-induced diarrhea via a
number of mechanisms that may include direct eﬀects on
gastrointestinal motility and the enteric nervous system [30].
In a separate study, patients with IBS were treated with
Biﬁdobacterium infantis or Lactobacillus salivarius (1E10)
in malted milk or malted milk alone (as a placebo) for
8weeks; there was a signiﬁcant reduction in abdominal
pain, discomfort, bloating, distension, and bowel movement
diﬃculty in patients who received Biﬁdobacterium infantis
compared with those who had placebo [90].
The use of multispecies probiotics has shown favorable
eﬀects in improving symptoms of IBS. VSL#3 contains
a mixture of diﬀerent bacterial species including Lacto-
bacillus species (L. casei, L. plantarum, L. acidophilus, and
L. delbrueckii), Biﬁdobacterium species (B. longum, B. breve,
and B. infantis), and Streptococcus thermophilus.Ar a n d o m -
ized controlled trial showed that the oral administration of
VSL#3, twice daily for 8weeks, signiﬁcantly reduced abdom-
inal bloating, but not other parameters (colonic transit time,
bowel dysfunction, abdominal pain, ﬂatulence, or urgency)
in a subgroup of diarrhea predominant IBS patients, when
compared with placebo [92]. In a second study targeting
48 IBS patients with bloating, VSL#3 signiﬁcantly reduced
ﬂatulence and colonic transit compared with the placebo
group [93].
In summary, many clinical trials have investigated the
therapeutic beneﬁts of probiotics in patients with IBS.
However, diﬀerences in duration of therapy, heterogeneity in
speciesorstrainsofselectedbacteria,anddiﬀerencesinchar-
acteristics of the enrolled patients have resulted in inconsis-
tent results.
5.5.2. Prebiotics. Prebiotics are nondigestible dietary sup-
plements that aﬀect the host by stimulating the growth of
beneﬁcial bacteria in the colon. Prebiotics have the capability
to stimulate only microbes which are already residing in
the gut [94]. Prebiotics are fermented by host bacteria
and have been associated with a reduction in the level
of triglyceride, improvement of the postprandial glucose
level and a reduction in intestinal permeability [3, 95]. The
fermentation of prebiotics leads to the production of SCFAs
such as butyric acids, which can serve as energy source for
intestinal epithelial cells [94]. When galactooligosaccharides
are used as prebiotics, they are known to stimulate gut
biﬁdobacteria in IBS patients and, thereby, reduce the
symptoms of IBS [96]. A potential limitation of prebiotic
treatment is that prebiotics undergo fermentation and could
produce bloating and ﬂatulence [97].
5.5.3. Synbiotics. Synbiotics are deﬁned as a combination of
probiotics and prebiotics [98]. One study has shown that a
combination of Biﬁdobacterium spp. and a prebiotic, inulin,
signiﬁcantly increased the quantity of Biﬁdobacteria.F u r -
thermore, prebiotics also help passage of probiotics through
the upper gastrointestinal tract and facilitate their establish-
ment in the colon [91]. However, data on synbiotics in var-
ious gastrointestinal diseases including IBS is scanty.
5.5.4. Prokinetics. Prokinetic drugs increase gastrointestinal
motility.Asimpairedgutmotilityisassociatedwithdysbiosis
and SIBO, prokinetics could beneﬁt IBS patients through an
eﬀect on the microbiota [99]. However, studies reporting the
use of erythromycin for the treatment of IBS have shown
limited eﬃcacy [100]. Furthermore, domperidone and cis-
apride were not always eﬀective for the treatment of IBS. In
anyevent,cisapridehasbeenwithdrawnfromthemarketdue
to adverse cardiac eﬀect [101].
5.5.5.Antibiotics. Asdiscussedinprevioussections,accumu-
lating data support the role of bacteria in the etiology of IBS
[102–104], and studies using antibiotics to target the intesti-
nal microbiota to treat IBS are now emerging. In a double
blind, randomized placebo-controlled study, neomycin was
more eﬀective than placebo in reducing IBS symptoms.
However, the use of neomycin in the treatment of IBS has
been limited by a marginal degree of eﬃcacy above placebo
and side eﬀects [61].International Journal of Inﬂammation 9
Rifaximin, derived from rifamycin, is highly concen-
trated in the gut lumen and has little systemic absorption.
It has been used in the treatment of traveller’s diarrhea and
SIBO. In a recent, large, double-blind, placebo-controlled
trial, in which subjects were administered 550mg rifaximin
3 times daily for 2weeks and followed up for 10weeks,
there was a signiﬁcant reduction in global IBS symptoms
in the rifaximin group in comparison to placebo (40.8%
versus 31.2%). In addition, there was a signiﬁcantly greater
reduction in bloating in those who received rifaximin
compared to placebo (40.2% versus 30.3%) [89, 103, 105].
A combination of probiotics and antibiotics may play a
beneﬁcial role in the treatment of IBS symptoms [3]. Pro-
biotics may increase the eﬃciency of antibiotics and reduce
gastrointestinal pathogens by the production of antibacterial
molecules including bacteriocins [3].
6. Summary and Conclusions
The literature on PI-IBS, SIBO, the relationship between gut
microbiota and GI sensorimotor functions, and the potential
for probiotics and antibiotics to alter these functions and
to improve some of the symptoms of IBS, taken together,
provide strong evidence in support of a major role for the
gut microbiota in the pathogenesis of IBS. This concept
represents a potential paradigm shift in our understanding
of the underlying mechanism (for at least a subset of patients
with IBS) from that of IBS as an entirely psychosomatic
disorder to that of a more organic disorder related to an
altered gut microbiota and low-grade inﬂammation. This
could, ultimately, lead to a potential change in the manage-
ment of IBS to strategies that alter the gut microbiota and
inﬂammation.
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